Biocon jumped 4.19% to Rs 328.55 after the company announced the signing of an exclusive licensing and supply agreement with South Korea-based Handok for the commercialization of its vertically integrated & complex drug product Synthetic Liraglutide.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.